PERCENT
Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC
Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%
Exact Sciences plans ‘transformative year’ with 3 cancer test debuts
Science, MRD, Exact brand biomedical or dental material, Hypersensitivity
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases
Regeneron crumples under the weight of missed Eylea expectations
Regeneron, United States Food and Drug Administration, earnings, Eylea, decline, Sales – occupational activity
J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing
Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Sanofi’s Altuviiio closing in on blockbuster status, Dupixent sales surge
Altuviiio, Sales – occupational activity, sanofi, Dupixent, United States Food and Drug Administration
Mercks Gardasil sales sink further amid China market pressure
Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China